Background: Preoperative reduced left ventricular ejection fraction (LVEF) is a prognostic factor for postoperative mortality following cardiovascular surgery. We investigated the relationship between the LVEF and the outcome of total arch replacement (TAR) in patients with subacute/chronic type A aortic dissection (TAAD).Methods: A total of 136 patients with subacute/chronic TAAD who received a TAR at Beijing Anzhen hospital from January 2015 to January 2018 were included in the analysis. Univariable and multivariable Cox proportional hazards regression analyses were performed to assess the relationship between the LVEF and the surgical outcome in this subset of patients. Results:The in-hospital mortality rate 4.4%, and 6.6% of patients experienced neurologic complications.During the median follow-up period of 3.97 years [interquartile range (IQR) 3.20-4.67 years], the all-cause mortality was 10.3% (14/136). The multivariable Cox proportional hazards analysis demonstrated that reduced LVEF was an independent predictor of mid-term mortality (hazards ratio =0.93, 95% CI: 0.86-0.99, P=0.03). The Kaplan-Meier survival analysis showed that patients with a LVEF <55% had a significantly worse prognosis than those with a LVEF ≥55%.Conclusions: During the mid-term follow-up period, subacute/chronic TAAD patients had a satisfactory surgical survival rate following TAR. Patients with a reduced LVEF had higher postoperative mortality following TAR. Thus, subacute/chronic TAAD patients with LVEF <55% should be carefully evaluated to determine their suitability for elective repair with TAR.
Background: Stanford type A aortic dissection (STAAD) is often associated with coronary artery problems requiring coronary artery bypass grafting (CABG). However, the prognosis of different proximal graft locations remains unclear.Methods: From May 2015 to April 2020, 62 patients with acute STAAD who underwent aortic surgery concomitant with CABG were enrolled in our study. Aortic bypass was defined as connecting the proximal end of the vein bridge to the artificial aorta (SVG-AO); non-aortic bypass was defined as connecting the proximal end of the vein bridge to a non-aorta vessel, including left subclavian artery, left common carotid artery, and right brachiocephalic artery (non-SVG-AO). We compared early- and mid-term results between patients in the above two groups. Early results included death and bleeding, and mid-term results graft patency, aortic-related events, and bleeding. Grafts were evaluated by post-operative coronary computed tomography angiography. According to the Fitzgibbon classification, grade A (graft stenosis <50%) is considered a patent graft. Univariate and multivariate analyses were performed to assess differences between aortic and non-aortic bypass in STAAD.Results: SVG-AO and non-SVG-AO were performed in 15 and 47 patients, respectively. There was no significant difference in death (log-rank test, p = 0.426) or bleeding (p = 0.766) between the two groups in the short term. One year of follow-up was completed in 37 patients (eight in the SVG-AO group and 29 in the non-SVG-AO group), among which 14/15 (93.3%) grafts were patent in the SVG-AO group and 32/33 (97.0%) grafts in the non-SVG-AO at 1 week, without a significant difference (p = 0.532). At 3 months, 12/13 (92.3%) grafts were patent in the SVG-AO group and 16/32 (50.0%) grafts in the non-SVG-AO, with a significant difference (p = 0.015), and 12/13 (92.3%) grafts in the SVG-AO group and 15/32 (46.9%) grafts in the non-SVG-AO group were patents, with a significant difference. Multivariate analysis showed proximal aortic bypass and dual anticoagulation to be protective factors for the 1-year patency of grafts.Conclusion: In patients requiring aortic dissection surgery with concomitant CABG, no differencess' between SVG-AO and SVG-non-AO in early outcomes were detected, but SVG-AO may have higher mid-term patency.
Background Simultaneous carotid endarterectomy (CEA) combined with coronary artery bypass grafting (CABG) has been widely used in patients with coronary heart disease complicated with severe carotid stenosis to reduce the risk of stroke and death. Carotid artery stenting (CAS) has been proven to be an alternative to CEA in recent years. We investigated the early and mid-term outcomes of simultaneous CEA or CAS combined with CABG in these patients. Methods From January 2011 to January 2021, 88 patients who underwent simultaneous carotid revascularization combined with CABG under the same anesthesia in Beijing Anzhen Hospital were retrospectively analyzed, and this study included 25 patients who underwent CAS–CABG and 63 patients who underwent CEA–CABG. The main outcomes included all-cause death, stroke, myocardial infarction and combined adverse events. The main outcomes of the two groups were compared at 30 days after the operation and the mid-term follow-up. Univariate and multivariate Cox proportional hazards regression analyses were performed to determine the independent risk factors affecting mid-term mortality. Results Within 30 days after the operation, there was no significant difference in combined adverse events between the two groups (P = 0.88). During the median follow-up period of 6.69 years (IQR, 5.82–7.57 years), 9 patients (14.30%) in the combined CEA–CABG group died, while 1 patient (4.00%) in the combined CAS–CABG group died. There were no significant differences in mid-term death (P = 0.20), stroke (P = 0.78), myocardial infarction (P = 0.88), or combined adverse events (P = 0.62) between the two groups. Univariate and multivariate Cox proportional hazards regression showed that NYHA grade IV (HR 5.01, 95% CI 1.16–21.64, P = 0.03) and previous myocardial infarction (HR 5.43, 95% CI 1.01–29.29, p = 0.04) were independent risk factors for mid-term mortality. We also found that combined CEA–CABG surgery may be associated with a higher risk of death (HR, 13.15; 95% CI 1.10–157.69, p = 0.04). Conclusions Combined CAS–CABG is a safe and effective treatment for patients with coronary heart disease complicated with severe carotid stenosis. NYHA grade IV and previous MI were independent risk factors for mid-term mortality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.